Mainz Biomed N.V. (NASDAQ:MYNZ) currently has a daily average trading volume of 1.55M but it saw 3355359 shares traded in last market. With a market cap of 5.56M USD, the company’s current market price of $0.25 came falling about -7.36 while comparing to the previous closing price of $0.27. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.48 and as low as $0.25. In the recent trading on the day, stock has struck highest price mark of $0.23 while lowest mark touched by it was $0.295.
Taking a look at 20-day trading activity of Mainz Biomed N.V. (MYNZ) gives us an average price of $0.3409, while its current price level is -92.70% below from 52-week high level whereas it is 0.43% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.3600 while that of 200 days or SMA-200 reads an average of $0.7682. A closer look into the stock’s movement over the week reveals that its volatility is standing at 18.69% during that period while stretching the period over a month that decreases to 16.07%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.48 which implies that the stock is in neutral territory.
Over the week, MYNZ’s stock price is moving -19.41% down while it is -34.43% when we observe its performance for the past one month. Year-to-date it is -78.09% down and over the past year, the stock is showing a downside performance of -92.30%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.56 beaten by the consensus estimate of -0.42 for the same. The company is expected to be releasing its next quarterly report in October, for which analysts forecasted an EPS of -0.25 while estimate for next year EPS is -0.87. In next quarter, company is expected to be making quarterly sales of $300k as analysts are expecting the sales for current fiscal year at $1.2M and seeing the company making $2.3M in sales next year. Moreover, analysts are in estimates of $220k for current-quarter revenue.
Currently, Mainz Biomed N.V.’s total number of outstanding shares is 21.17M. Company’s return on investment (ROI) stands at -595.61%. Stock’s beta reads 0.14. Stock has a price to book (P/B) ratio of 1.66 while price to sale or P/S ratio amounts to 6.18.
